Covestor LTD Erasca, Inc. Transaction History

Covestor LTD

$160 Million
Q3 2024

A detailed history of Covestor LTD transactions in Erasca, Inc. stock. As of the latest transaction made, Covestor LTD holds 40 shares of ERAS stock, worth $108. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 43 6.98%

Holding current value

$108

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	SELL	$2.17 - $3.28 $6 - $9	-3 Reduced 6.98%	40 $0
Q1 2024 May 10, 2024	BUY	$1.67 - $2.55 $33 - $51	20 Added 86.96%	43 $0
Q4 2023 Feb 09, 2024	SELL	$1.67 - $2.49 $3 - $4	-2 Reduced 8.0%	23 $0
Q3 2023 Nov 13, 2023	SELL	$1.97 - $2.91 $7 - $11	-4 Reduced 13.79%	25 $0
Q2 2023 Aug 11, 2023	SELL	$2.57 - $3.3 $2 - $3	-1 Reduced 3.33%	29 $0
Q1 2023 May 15, 2023	BUY	$2.74 - $4.44 $38 - $62	14 Added 87.5%	30 $0
Q4 2022 Feb 13, 2023	SELL	$3.89 - $8.57 $3 - $8	-1 Reduced 5.88%	16 $0
Q3 2022 Nov 14, 2022	SELL	$5.82 - $10.68 $17 - $32	-3 Reduced 15.0%	17 $0
Q2 2022 Aug 10, 2022	SELL	$4.58 - $8.72 $27 - $52	-6 Reduced 23.08%	20 $0
Q1 2022 May 13, 2022	BUY	$8.6 - $15.48 $223 - $402	26 New	26 $0

Others Institutions Holding ERAS

# of Institutions

141

Shares Held

229M

Call Options Held

28.7K

Put Options Held

117K

Frazier Life Sciences Management, L.P. Menlo Park, CA

19.4M
Shares

$52.4 Million
2.85% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

16.8M
Shares

$45.4 Million
0.03% of portfolio
Vr Adviser, LLC New York, NY

16.2M
Shares

$43.8 Million
4.58% of portfolio
Suvretta Capital Management, LLC New York, NY

13.8M
Shares

$37.2 Million
1.48% of portfolio
Vanguard Group Inc Valley Forge, PA

13.3M
Shares

$35.9 Million
0.0% of portfolio

View Full List

About Erasca, Inc.

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $330M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

More about ERAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

News

Stay updated on Covestor LTD with notifications on news.

Account